Skip to content
OpenCapital
Get started

BridgeBio Pharma BBIO Research and Development Services — Contract with customer, liability

Similar metrics at other companies

Ionis Pharmaceuticals logo
IONSResearch And Development Services — Payments Included In Transaction Price For Performance Obligation
$582M—
Ionis Pharmaceuticals logo
IONSResearch And Development Services — Revenue From Contract With Customer Transaction Price
$582M—
Cytokinetics logo
CYTKResearch And Development — Accounts Receivable Net Current
$1.7M-48.5%
Ionis Pharmaceuticals logo
IONSResearch And Development Revenue — Cumulative Payments Included In Transaction Price For Performance Obligation
$90M—
Cytokinetics logo
CYTKResearch And Development — Revenue
$500K+25.0%
Cytokinetics logo
CYTKResearch And Development Milestone Grant And Other Revenues Net — Accounts Receivable Net Current
$0-100%

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K—
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$12.98B+119%
Enterprise value$15.36B+178%
P/S22.4×-24.1×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%—

Returns & leverage

See full
Return on equity-216.8%—
Debt / equity2×—
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's research and development services — contract with customer, liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BridgeBio Pharma's research and development services — contract with customer, liability?
BridgeBio Pharma (BBIO) reported research and development services — contract with customer, liability of $2.7M in Q1 2026.
What does research and development services — contract with customer, liability mean?
The total amount of money received from customers for R&D services that the company has not yet earned by completing the work.
How do you interpret research and development services — contract with customer, liability?
An increase suggests strong upfront payments or milestone funding for future R&D, while a decrease indicates the company is successfully delivering on its service obligations.
How does research and development services — contract with customer, liability compare across companies?
Standard in companies utilizing milestone-based or upfront-payment revenue recognition models in pharmaceutical development.